Finding Specialists and Paying for Services
- Introduction to Clinical Trials
- Research Findings
- Studies Enrolling Patients
- Research Collaborations
PARP Inhibitor Breast Cancer Trials By Name
PARP Inhibitor Breast Cancer Clinical Trials Listed by Drug Name
The below studies are PARP inhibitor studies that are currently enrolling patients with breast cancer listed by drug name. For more details on an individual study, please contact the study coordinator or visit clinicaltrials.gov.
Abbott: Veliparib (ABT-888)
- NCT01306032: ABT-888 (veliparib)With Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian TubeCancer, Triple-NegativeBreast Cancer, and Low-Grade Non-Hodgkin's Lymphoma
- NCT01104259: Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer
- NCT01149083: Veliparib With or Without Carboplatin in Treating Patients With Stage III or Stage IV Breast Cancer
- NCT01251874: Veliparib and Carboplatin in Treating Women With HER2-Negative Metastatic Breast Cancer
- NCT00892736: ABT-888 in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy
- NCT01281150: Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
- NCT01042379: I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
AstraZeneca: Olaparib (AZD-2281)
- NCT01237067: Olaparib in Combination With Carboplatin for Refractory or Recurrent Women's Cancers
- NCT00647062: AZD2281 and Carboplatin in Treating Patients With BRCA1/BRCA2-Associated, Hereditary, or Triple Negative Metastatic or Unresectable Breast Cancer or Ovarian Epithelial Cancer
- NCT01445418: AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer
BioMarin:
- NCT01286987: Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Cephalon
Clovis: Rucaparib (formerly PF-01367338)
- NCT01482715: A Study of Oral Rucaparib in Patients With gBRCA Mutation Breast Cancer or Other Solid Tumor
- NCT01074970: PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)or BRCA1/2 Mutations
Sanofi-Aventis: Iniparib (BSI 201)
- NCT00813956: A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (PARP Inhibitor also known as iniparib) in the Neoadjuvant Treatment of Triple Negative Breast Cancer
- NCT01173497: A Study Evaluating Iniparib in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Page updated 01/10/12
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.